News

Alamar Biosciences, Inc.: Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ ...
Worried about Alzheimer’s? Start walking, according to a new 10-year study
As you age, maintaining a daily habit of walking can prevent cognitive decline, especially for those most at risk, a new ...
Cantech Letter16m
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at ...
GEN Ilaç ve Saglik Ürünleri A.S.: GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable ph ...
The Manila Times23m
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation ...
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from their ...
Alzheimer's may be delayed through lifestyle changes, especially walking, new studies show
New research builds on evidence that diet, certain brain training exercises and physical activity can delay the decline of ...
Clinical Trials Arena56m
Roche’s Alzheimer’s therapy shows continued benefit
Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.
Researchers discover how microglia engulf and break down amyloid beta, a protein that builds up in Alzheimer's
Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer's disease, ...